NCT04577703 is a Phase 1 clinical trial of CT053PTSA in Advanced Solid Tumors, sponsored by Sunshine Lake Pharma Co., Ltd..

Who is sponsoring NCT04577703?

NCT04577703 is sponsored by Sunshine Lake Pharma Co., Ltd..

What drugs are being tested in NCT04577703?

Interventions in NCT04577703: CT053PTSA.

What condition does NCT04577703 study?

NCT04577703 studies Advanced Solid Tumors.

Is NCT04577703 still recruiting?

NCT04577703 is currently completed. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT04577703

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Completed Phase 1 Last updated 8 October 2020

What this trial tests

Phase 1 trial testing CT053PTSA in Advanced Solid Tumors in 20 participants. Completed in 10 December 2015.

Timeline

8 February 2014

Primary endpoint
10 December 2015

10 December 2015

Quick facts

Lead sponsor	Sunshine Lake Pharma Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	8 February 2014
Primary completion	10 December 2015
Estimated completion	10 December 2015
Sites	1 location across China

Drugs / interventions tested

CT053PTSA — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Sunshine Lake Pharma Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecule inhibitors targeting the cancers.
Liu GH, Chen T, Zhang X, Ma XL, et al · · 2022 · cited 127× · PMID 36254250 · DOI 10.1002/mco2.181
Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer.
Yan D, Earp HS, DeRyckere D, Graham DK. · · 2021 · cited 27× · PMID 34830794 · DOI 10.3390/cancers13225639
Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy.
Mikolajczyk A, Mitula F, Popiel D, Kaminska B, et al · · 2022 · cited 13× · PMID 35626092 · DOI 10.3390/cancers14102488
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX, Liu FR, Zhang Y, Chen Q, et al · · 2022 · cited 8× · PMID 36341335 · DOI 10.3389/fimmu.2022.1024755
Structure and functions of Mer, an innate immune checkpoint.
Ubil E, Zahid KR. · · 2023 · cited 5× · PMID 37936688 · DOI 10.3389/fimmu.2023.1244170

Verify or expand the search:

Other trials of CT053PTSA

Trials testing the same drug.

NCT04992858 — Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations · Phase 2 · unknown
NCT03876925 — A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC · Phase 1, PHASE2 · terminated
NCT03125876 — A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) · Phase 1 · terminated

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Sunshine Lake Pharma Co., Ltd. trials

Trials by the same sponsor.

NCT07341672 — A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itrac · Phase 1 · not yet recruiting
NCT05048368 — Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function · Phase 1 · not yet recruiting
NCT07376200 — Single-ascending Dose Study of HEC-151 Injection · Phase 1 · not yet recruiting
NCT07082842 — Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF · Phase 3 · not yet recruiting
NCT07211165 — Clinical Study on the Mass Balance of Clifutinib · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04577703 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunshine Lake Pharma Co., Ltd.
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04577703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing